Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CAEP
Cantor Equity Partners III
$10.37
-0.8%
$0.00
$10.30
$11.09
$317.12MN/A205,335 shs6,869 shs
DMAA
Drugs Made In America Acquisition
$10.25
+0.2%
$0.00
$9.95
$10.28
$298.99MN/A102,865 shs7,701 shs
DNI
Dividend and Income Fund
$9.79
$9.76
$6.55
$13.97
$121.89M1.3363,824 shs88,009 shs
HYAC
Haymaker Acquisition Corp. 4
$11.19
-0.1%
$0.00
$10.59
$11.20
$330.66M-0.02105,256 shs86,401 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CAEP
Cantor Equity Partners III
-0.29%-0.85%-1.14%+1,044,999,900.00%+1,044,999,900.00%
DMAA
Drugs Made In America Acquisition
-0.49%-0.29%+1,022,999,900.00%+1,022,999,900.00%+1,022,999,900.00%
DNI
Dividend and Income Fund
0.00%0.00%0.00%0.00%0.00%
HYAC
Haymaker Acquisition Corp. 4
0.00%0.00%+1,119,999,900.00%+1,119,999,900.00%+1,119,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CAEP
Cantor Equity Partners III
N/AN/AN/AN/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
DNI
Dividend and Income Fund
N/AN/AN/AN/AN/AN/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CAEP
Cantor Equity Partners III
0.00
N/AN/AN/A
DMAA
Drugs Made In America Acquisition
0.00
N/AN/AN/A
DNI
Dividend and Income Fund
0.00
N/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CAEP
Cantor Equity Partners III
N/AN/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/AN/A
DNI
Dividend and Income Fund
N/AN/AN/AN/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CAEP
Cantor Equity Partners III
N/AN/A0.00N/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
DNI
Dividend and Income Fund
N/AN/A0.00N/AN/AN/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CAEP
Cantor Equity Partners III
N/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/A
DNI
Dividend and Income Fund
$0.959.70%N/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/AN/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
CAEP
Cantor Equity Partners III
230.58 millionN/AN/A
DMAA
Drugs Made In America Acquisition
229.17 millionN/AN/A
DNI
Dividend and Income Fund
N/A12.45 millionN/ANot Optionable
HYAC
Haymaker Acquisition Corp. 4
N/A29.55 million23.00 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cantor Equity Partners III NASDAQ:CAEP

$10.37 -0.08 (-0.77%)
As of 01:31 PM Eastern

We are a blank check company incorporated on November 11, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any discussions, directly or indirectly, with any business combination target regarding an initial business combination with our company. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we expect to focus on a target in an industry where we believe our management team’s and our affiliates’ expertise will provide us with a competitive advantage, including the financial services, digital assets, healthcare, real estate services, technology and software industries. Further, our efforts to identify a prospective target business will not be limited to any characteristics, although we expect to favor potential target companies with certain characteristics which include, but are not limited to, positive long term growth prospects, competitive advantages, consolidation opportunities, recurring revenue or the potential for recurring revenue, opportunities for operational improvement and attractive margins or the potential for attractive margins. Our executive offices are located New York, New York.

Drugs Made In America Acquisition NASDAQ:DMAA

$10.25 +0.02 (+0.20%)
As of 11:59 AM Eastern

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.

Haymaker Acquisition Corp. 4 NYSE:HYAC

$11.19 -0.01 (-0.09%)
As of 09:42 AM Eastern

Haymaker Acquisition Corp. 4 is a blank check company. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. Haymaker Acquisition Corp. 4 is based in New York.